SERAM 2014 / S-0483
Criterios RANO en la evaluación de respuesta terapéutica de gliomas de alto grado. Nuestra experiencia.
Keywords:
Neoplasia, Structured reporting, MR, Neuroradiology brain
Authors:
F. Facal de Castro, J. Forner, R. Mirón Mombiela, W. Severino Rondón, A. Carreres Ortega, F. Mata Escolano; Valencia/ES
DOI:
10.1594/seram2014/S-0483
Bibliografía
- Chinot O,
Macdonald DR,
Abrey L,
Zahlmann G,
Kerlowguen Y,
cloughesy T.
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trial of Antiogenic Therapy.
Curr Neurol Neurosci Rep (2013); 13: 347.
- Macdonald DR,
Casino TL,
Schold Jr SC,
et al.
Response criteria for phase II studies of supratentorial malignant gliomas.
J Clin Oncol 1990; 8 1277-80.
- Wen PY,
Macdonald DR,
Reardon DA,
et al.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
J Clin Oncol 2010; 28: 1963-72.
- Stupp R.
Mason WP,
Van Den Bent MJ,
et al.
Radiotheraphy plus concomitant and adjuvant temozolamide for glioblastomas.
The New England Journal of Medicine,
2005; 352 (10): 987-96.
- Wit MCY,
Bruin HG,
Eijkenboom W,
Sillevis Smith PAE,
Van Den Bent MJ.
Inmediate post-radiotherapy changes in malignant gliomas can mimic tumor progression.
Neurology,
2004; 62(3): 624-28.
- Sanguera P,
Perry J,
Sahganl A,
et al.
Pseudoprogresion following chemoradiotherapy for glioblastoma multiforme.
Canadian Journal of Neurological Sciences,
2010; 37: 36-42.
- Linhares P,
Carvalho B,
Figueiredo R,
Reis RM,
Vas R.
Early Pseudoprogression Followin Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.
Journal of Oncology 2013; ID: 690585: 1-9.
- Henegar MM,
Moran CJ,
Silbergeld DL.
Early postoperative magnetic resonance imagin following nonneoplasic cortical resection.
J Neurosurg,
1996; 84: 174-79.
- Radbrunch A,
Lutz K,
Wiestler B,
Baumer P,
Heiland S,
Wick W,
Bendszus M.
Relevance of T2 signal changes in the assestment of progression of glioblastoma according to the Response Assesstment in Neurooncology criteria.
Neuro Oncology,
2012; 14: 222-29.
- Pérez-Larraya JG,
et al.
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonal,
RECIST,
RANO,
and RECIST + criteria.
Neuro Ongology,
2012; 14: 667-673.
